Weight-loss drugs should be covered by Medicare and by other health insurance, according to a poll of US adults aged 50-80 years.
Among more than 2600 polled, 83% say that health insurance should cover prescription weight-loss drugs that have been approved by the US Food and Drug Administration (FDA), and 76% say Medicare should cover such drugs. However, only 30% would be willing to pay higher Medicare premiums to have these medications covered.
Among the 27% of respondents who say they are overweight, 63% are interested in taking such medications, as are 45% of those with diabetes, regardless of weight.
The University of Michigan (U-M) National Poll on Healthy Aging was published online on December 13, 2023.
High Awareness
The findings come at a time when injectable glucagon-like peptide 1 receptor agonists (GLP-1 RAs), such as Ozempic, Wegovy, Zepbound, and Mounjaro, are receiving a lot of public attention, the university noted.
Overall, 64% of survey respondents had heard of at least one prescription medication used for weight management.
By brand name, 61% had heard of Ozempic, approved for the treatment of type 2 diabetes but prescribed off label for weight loss; 18% had heard of Wegovy; and 13% had heard of the anorexiant drug phentermine.
Very few respondents (3% for each) had heard of the GLP-1 RA Saxenda, Qsymia (phentermine plus the anticonvulsant topiramate), and the opiate antagonist Contrave.
Zepbound, the obesity-specific form of the diabetes drug Mounjaro, received FDA approval after the poll was taken and was not included in survey questions.
Among respondents who had heard of at least one prescription medication used for weight management, 58% had heard about them through the news (eg, TV, magazines, newspapers) and 53% had heard about them from an advertisement on TV, the internet, or radio. Only 11% heard about them from their healthcare provider.
Respondents more likely to be interested in taking a prescription medication for weight management included women, those aged 50-64 years, Black persons, Hispanic persons, those with household incomes of less than $60,000 annually, those with lower levels of education, those in fair or poor physical or mental health, and those with a health problem or disability limiting their daily activities.
Spotty Coverage
The GLP-1 RAs can cost more than $12,000 a year for people who pay out of pocket, the university noted.
A Medicare Part D law passed in 2003 prohibits Medicare from covering medications for weight loss, although currently it can cover such drugs to help people with type 2 diabetes manage their weight.
Medicaid covers the cost of antiobesity drugs in some states.
Most private plans and the Veterans Health Administration cover them, but with restrictions due to high monthly costs for the newer medications.
The American Medical Association recently called on insurers to cover evidence-based weight-loss medications.
The strong demand for these medications, including for off-label purposes by people willing to pay full price, has created major shortages, the university noted.
"As these medications grow in awareness and use, and insurers make decisions about coverage, it's crucial for patients who have obesity or diabetes, or who are overweight with other health problems, to talk with their healthcare providers about their options," said poll director Jeffrey Kullgren, MD, MPH, MS, a primary care physician at the VA Ann Arbor Healthcare System and associate professor of internal medicine at U-M.
Other weight-management strategies that respondents think should be covered by health insurance include sessions with a registered dietitian or nutritionist (85%); weight-loss surgery (73%); gym or fitness facility memberships (65%); apps or online programs to track diet, exercise, and/or behavior change (58%); and sessions with a personal trainer (53%).
The randomly selected nationally representative household survey of 2657 adults was conducted from July 17 to August 7, 2023, by NORC at the University of Chicago for the U-M Institute for Healthcare Policy and Innovation. The sample was subsequently weighted to reflect population figures from the US Census Bureau. The completion rate was 50% among those contacted to participate. The margin of error is ±1 to 5 percentage points for questions asked of the full sample and higher among subgroups.
The poll is based at the U-M Institute for Healthcare Policy and Innovation and supported by AARP and Michigan Medicine, the University of Michigan's academic medical center.
Comments